Objective-Interleukin (IL)-6 -mediated inflammation is involved in cardiovascular disease (CVD). We assessed IL-6 levels and the Ϫ174GϾC genotype in a case-control study of men and women (average age 73 years) within the Cardiovascular Health Study. Methods and Results-Cases included incident angina, myocardial infarction (MI), and stroke (5-year follow-up), prevalent MI, and MRI-detectable infarcts. A control group and a group free of subclinical CVD were used for comparison. The Ϫ174C allele was associated with higher C-reactive protein (11% higher, Pϭ0.02), fibrinogen (3% higher, Pϭ0.02), and IL-6 (5% higher; Pϭ0.16). IL-6 was associated with increased atherosclerosis when the control group was compared with the group free of subclinical CVD. No further association with CVD events was found when case groups were compared with the control group. Compared with its absence, presence of the Ϫ174C allele was associated with risk of MRI infarcts (odds ratio 1.5). Conclusions-IL-6 levels differentiated those with subclinical CVD from those without. Although the Ϫ174C allele was not associated with incident events, associations of the genotype with inflammation and MRI infarcts, combined with the plasma IL-6 results, suggest that IL-6 may chronically predispose an individual to develop atherosclerosis.
I nflammation is recognized as a central component of cardiovascular disease (CVD), although the underlying regulation and molecular mechanisms remain unclear. 1 Interleukin (IL)-6, a key inflammatory cytokine, is involved in a diverse range of biological activities, in particular, the synthesis of acute-phase reactants by the liver. 2,3 IL-6 levels are normally very low and increase during infection, trauma, or stress, and they also increase with age. 4 Elevated levels of IL-6 are associated with an increased risk of death from cardiovascular and noncardiovascular causes in the elderly [5] [6] [7] [8] and with myocardial infarction (MI) in middle-aged men. 9 Elevated levels of C-reactive protein (CRP) and fibrinogen, acute-phase reactants largely regulated by IL-6, 2,3 are also independently associated with risk of CVD 10, 11 over long time periods.
Our underlying hypothesis is that atherosclerosis represents a chronic inflammatory disorder and that elevated IL-6 levels may predict risk of future CVD events. In addition, polymorphisms in the 3Ј-and 5Ј-untranslated regions of the IL-6 gene may be key regulators of IL-6 and downstream protein levels and therefore may predispose an individual to CVD risk as well.
The Ϫ174GϾC promoter polymorphism in the IL-6 gene may involve one such site of regulation. The Ϫ174GϾC polymorphism has demonstrated functionality in vitro and in healthy middle-aged white men. 12 In middle-aged men, the Ϫ174C allele was not associated with fibrinogen but was associated with higher blood pressure and conveyed a modestly higher relative risk (RR) for coronary heart disease (RR 1.54, 95% CI 1.02 to 2.23), particularly evident in smokers (RR 2.66, 95% CI 1.60 to 4.32) . 13 The Ϫ174GϾC genotype may also contribute to susceptibility to type 1 diabetes 14, 15 and lipid abnormalities. 15, 16 Because a large fraction of CVD events occurs in people aged Ͼ65 years and because the IL-6 promoter polymorphism has not been studied extensively in women, we examined the effects of plasma IL-6 and the Ϫ174GϾC genotype on CVD risk in a subset of the elderly men and women of the Cardiovascular Health Study (CHS).
Methods

Cardiovascular Health Study
The original CHS cohort (5201 adults aged Ն65 years) was recruited from 1989 to 1990. 17 An additional cohort of 687 African American participants (minority cohort) was recruited between 1992 and 1993. Examinations included lifestyle and medical histories, including assessment of the prevalence and extent of clinical CVD, 17 physical exams, blood collection, resting 12-lead echocardiography, 18 anklearm blood pressure index (AAI), 19 and carotid ultrasonography. 20 Cerebral MRI was performed between 1992 and 1994. 21 All subjects gave informed consent for participation in the study, and all procedures were conducted under institutionally approved protocols for use of human subjects.
Ascertainment of Events
Incident events in this case-control study occurred between baseline and June 30, 1995, and were adjudicated by a committee using standardized and published criteria. 22 Case groups consisting of original cohort individuals free of clinical CVD at baseline included incident MI (nϭ217), stroke (nϭ208), and angina (nϭ226) and MRI-detectable infarcts (MRI infarcts, nϭ250). A subclinical CVDfree reference group (nϭ250) consisted of the original cohort of individuals free of prevalent and incident CVD who met the following criteria: maximum internal carotid intima-media thickness (IMT) Յ the 20th percentile, AAI Ն1.00, carotid stenosis Յ25%, no major ECG abnormality, no abdominal aortic aneurysm, and no wall motion abnormalities on an echocardiogram. The control group (nϭ500) was composed of randomly selected original cohort members who had no prevalent or incident CVD and no MRI-detectable infarcts and who did not satisfy the criterion of being free of subclinical CVD. At the time of selection, there was insufficient follow-up of the minority cohort to include them in the case groups. A separate group of randomly selected minority cohort members free of prevalent CVD was added as a comparison (nϭ250). The prevalent MI case group (nϭ553) consisted of all subjects from both cohorts with confirmed MI at baseline.
Definitions
Prevalent CVD was defined as confirmed angina, MI, stroke, or transient ischemic attack. 17 Hypertension was defined as seated systolic blood pressure Ն160 mm Hg, diastolic pressure Ն95 mm Hg, or self-reported high blood pressure and use of antihypertensive medication. Borderline hypertension was seated systolic blood pressure of 140 to 159 mm Hg or diastolic pressure 90 to 94 mm Hg. Obesity was defined as body mass Ն130% of ideal body mass for age and sex, based on body mass index (BMI), which is weight (kg)/height (m 2 ). Smoking was classified as current, former, or never. Diabetic status was classified according to the American Diabetic Association. 23 Major ECG abnormalities and calculation of left ventricular mass (LVM) were previously defined. 24 Subclinical CVD was defined as follows: (1) AAI Յ0.9, (2) maximum common or internal carotid artery IMT Ն80th percentile, (3) carotid artery stenosis Ն25%, (4) presence of major ECG abnormalities, or (5) positive response for angina or intermittent claudication on the Rose questionnaire. 25
Laboratory Methods
Procedures for blood collection and laboratory methods have been reported. 26 The assays for fibrinogen (coefficient of variation [CV] 2.9%) and IL-6 (CV 6.3%) have also been described. 5, 26, 27 CRP was measured in a high-sensitivity assay developed in house (CV 8.9%). 28, 29 All assays were conducted on blood drawn at baseline.
Genotyping for IL-6 to 174G>C Promoter Polymorphism
Genotyping for the Ϫ174GϾC polymorphism was carried out as previously described. 12, 30 Genotyping was performed for 1857 white and 344 African American individuals who consented to DNA preparation and use for CVD analysis. CVD risk factor data were also available on these individuals. IL-6 levels were available on 1424 whites and 300 African Americans.
Statistical Analyses
Data were analyzed by using the Statistical Package for Social Science (SPSS) for Windows (version 10.0). 31 Associations of IL-6 levels with categorical variables representing CVD risk factors (sex, diabetes, hypertension, angina, and smoking) and subclinical CVD (major ECG abnormalities) were determined by ANOVA for individuals in the control group. Significance was set at PՅ0.05. Bivariate associations with continuous variables representing CVD risk factors (age, BMI, fasting glucose and insulin, blood pressure, physical activity, and lipids), measures of subclinical CVD (common and internal carotid IMT, AAI, and LVM), and inflammatory factors (CRP, fibrinogen, white blood cell count, and albumin) were determined by Pearson correlation coefficients.
Logistic regression was used to estimate risk associated with IL-6 quartiles; the control group was compared with the group free of subclinical CVD, and then the cases were compared with the controls. Analyses were adjusted for age, race, sex, and clinic site.
Differences in the Ϫ174 C allele frequency in selected white and African American participants were assessed by 2 tests. Associations of genotype with inflammatory markers, CVD risk factors, coagulation and fibrinolytic factors, and measures of subclinical disease were determined by ANOVA for continuous variables and by 2 statistics for categorical variables in the selected white population. Logistic regression was used to assess the association of genotype with CVD events.
Because of the association of IL-6 level and adiposity, 32, 33 we stratified on BMI and used 2-way ANOVA to examine the association of BMI (tertiles) and IL-6 genotype with selected variables. We likewise stratified on smoking (never versus current/former) because of the smoking-related changes in IL-6 and CRP levels. 34 -36 
Results
Distributions
Baseline characteristics of the CHS participants selected for the present study are shown in Table 1 . Control and case groups had similar levels of subclinical CVD, with 67% of men and 62% of women in the control group and 78% of men and 67% of women in the combined case groups having some form of subclinical CVD.
IL-6 levels did not vary by race when white control subjects were compared with the African American reference group (whites 1.86Ϯ1.82 pg/mL, African Americans 1.78Ϯ1.94 pg/mL; PϭNS). Levels were also similar when analyses were stratified on race and sex.
Genotype distribution and Ϫ174C allele frequency in controls (whites only) and African Americans (reference group) are shown in Table 2 . Genotype distributions were in Hardy-Weinberg proportions in both populations (both PϾ0.3); however, the Ϫ174C allele was significantly more common in whites than in African Americans (38% versus 8%, respectively; PՅ0.001). Because of the relatively small number of African American participants, genotype analyses were limited to whites.
Correlates
In controls, plasma IL-6 was associated with CVD risk factors (age, BMI, glucose, and insulin), lipids, measures of subclinical CVD (common and internal carotid IMT, AAI, and LVM), and inflammatory factors (CRP, fibrinogen, albumin, and white blood cell count), with most associations remaining significant when the cohort was stratified by sex.
Overall in case-control group whites, the Ϫ174C allele was associated with higher fibrinogen (Pϭ0.015) and CRP (Pϭ0.014), with a trend toward higher IL-6 (Pϭ0.163, Figure 1 ). Results were similar for men and women, but the associations were not significant in men. There were no associations of genotype with metabolic or CVD risk measures including the following: blood pressure, AAI, lipids, albumin, white blood cell count, obesity, carotid IMT, LVM, carotid stenosis, and ECG abnormalities.
We examined possible effect modification by adiposity ( Figure 2 ) and smoking. For those in the lowest BMI tertile, the presence of at least 1 C allele was associated with 20% higher CRP (Pϭ0.011), whereas only 8% higher levels (PϭNS) were seen in those in the highest BMI tertile. Similar results were seen for fibrinogen, and weaker associations were seen for IL-6. In current or former smokers, the Ϫ174C allele was associated with a greater difference in levels of CRP and fibrinogen than in never smokers. The formal test for interaction approached 
Prediction of Events
There were no significant differences in IL-6 levels between the controls and cases with angina, incident MI, or MRI infarcts (Table 1) . IL-6 was significantly higher in the stroke group (Pϭ0.009) and significantly lower in the subclinical CVD-free group (PՅ0.001) compared with the control group. All case groups (with the exception of prevalent MI, which lacked plasma IL-6 measurements) had significantly higher IL-6 levels (PՅ0.001) than the subclinical CVD-free group. In logistic regression, after adjustment for age, sex, race, and clinic site, higher IL-6 was not associated with incident CVD events or MRI infarcts when controls were the reference group (Table 3) . However, with the subclinical CVD-free group as the reference group, increasing levels of IL-6 were associated with subclinical CVD (Table 3 ) and with clinical CVD. Similar results were seen in men and women separately. In addition, in men, the association between the highest quartile and risk of stroke was also significant when the controls were used as the reference group (adjusted odds ratio [OR] 3.84, 95% CI 1.20 to 12.29).
Frequency of the Ϫ174C allele in selected CHS participants is shown in Table 1 . The C allele was more common in the MRI infarct group than in the control group (adjusted OR 1.50, 95% CI 1.05 to 2.14). There were no other significant associations with CVD events. Similar results were seen for men and women. In secondary analyses, stratifying on smoking revealed that the association of the C allele with MRI infarcts was primarily in nonsmokers (adjusted OR 1.70, 95% CI 1.01 to 2.88) and in the lowest BMI tertile (adjusted OR 2.37, 95% CI 1.25 to 4.49). When the subclinical CVD-free reference group was used, male nonsmokers with at least 1 C allele had a significantly increased OR for incident MI (adjusted OR 8.93, 95% CI 1.70 to 46.83), prevalent MI (adjusted OR 4.78, 95% CI 1.23 to 18.46), and MRIdetectable infarcts (adjusted OR 3.80, 95% CI 1.14 to 12.71). This association was not evident in women.
Discussion
The major findings of this population-based study of elderly individuals were as follows: (1) a strong correlation of plasma IL-6 with markers of subclinical CVD; (2) significantly higher ORs for subclinical and clinical CVD, with increased levels of IL-6 when those with subclinical and clinical CVD were compared with the subclinical CVD-free reference group, but no discrimination between those with CVD events Figure 2 . Association of BMI and genotype with inflammatory factors. BMI tertiles are numerical: 1 indicates lowest; 2, middle; and 3, highest. A, CRP (P genotype ϭ0.012, P BMI Յ0.001, and P interaction ϭ0.269). B, FGN (P genotype ϭ0.016, P BMI ϭ0.003, and P interaction ϭ0.229). C, IL-6 (P genotype ϭ0.155, P BMI Յ0.001, and P interaction ϭ0.260). Error bars are 95% CIs. and the controls with subclinical disease; (3) a general lack of association of IL-6 promoter genotype with metabolic measures and CVD risk factors; (4) a stronger association of genotype with inflammation and blood pressure in subgroups based on obesity and smoking, known correlates of inflammation; and (5) evidence from subset analyses suggesting that in never-smoking men the presence of a C allele was associated with increased CVD.
In the selected CHS sample, the level of subclinical CVD in the control group was similar to that in the case groups (Table 1) , and IL-6 levels were not predictive of CVD events when the controls were used as the reference group. However, when the subclinical CVD-free group was used for comparison, IL-6 levels were significantly associated with incident, prevalent, and subclinical CVD. Similarly, the Ϫ174C allele was associated with CVD events in nonsmoking men compared with the subclinical CVD-free group, supporting the position that the C allele may play an important role in the development of atherosclerosis, even in the absence of smoking. The lack of association in male current or former smokers may be due to survivor effects, inasmuch as there were fewer C allele carriers in this group compared with never smokers. However, the number of men in these subgroups is small, and our results need to be confirmed in future studies.
Our results are consistent with the position that adipose tissue is a major regulator of total circulating IL-6 32, 33 and may, in more obese individuals, overwhelm the contribution of the Ϫ174GϾC genotype to plasma levels. Cigarette smoking has likewise been reported to influence IL-6 expression 34, 35 and has been previously demonstrated to affect the association of CRP with other variables. 36 This suggests that the polymorphism may exert an influence in the presence of a constant inflammatory stimulus, such as that provided by smoking, but not in the presence of obesity.
These findings are in apparent contrast to a previous report 12 suggesting that the C allele was associated with lower IL-6 levels in a small group of younger healthy men and women. The conflicting results may be due to chance, although it is also possible that the Ϫ174GϾC polymorphism exhibits different effects in older individuals compared with younger healthier people. In support of this, a larger study of patients with aneurysmal disease found a strong association between the Ϫ174C allele and higher levels of IL-6. In addition, subjects with the C allele had a higher mortality during the 5-year follow-up of the trial. 37 The C allele has also been reported to be associated with risk of coronary heart disease in a case-control study. 38 Likewise, in a large cohort of healthy middle-aged men from the Second Northwick Park Heart Study (NPHS II), the C allele was associated with significantly higher systolic blood pressure, CRP levels, and risk of coronary artery disease. 13 In that study, smoking did not modify the effects of the C allele, and the effects of the C allele were more marked in men in the upper tertiles of BMI compared with the lowest tertile. These differences from our results may reflect survivor effects, inasmuch as the men and women of the CHS were considerably older than the men of NPHS II.
In summary, we report that in the CHS, plasma IL-6 appears to function as a marker for subclinical CVD and is associated with CVD events when individuals essentially free of subclinical CVD are used as a reference group. The Ϫ174GϾC promoter polymorphism appears to function in the regulation of IL-6 and acute-phase reactants influenced by IL-6 expression. However, the effects of the genotype are modified by environmental factors, such as adiposity, which may contribute more significantly to IL-6 production than genotype. Although the Ϫ174GϾC genotype does not appear to directly influence CVD risk in the elderly, the C allele appears likely to contribute to the development and progression of atherosclerotic disease.
